GenEng News  Jan 9  Comment 
Fifteen months after it was spun out of deCODE Genetics by Amgen with $15 million in venture capital, NextCODE Health has been acquired by WuXi PharmaTech for $65 million, expanding the Chinese R&D services company into the proverbial clinic by...
New York Times  Dec 10  Comment 
In a bid to bolster its drug discovery efforts, the biotechnology giant Amgen said on Monday that it would pay $415 million to acquire deCODE Genetics, a gene-hunting business known for its headline-grabbing discoveries linking genetic variations...
Wall Street Journal  Dec 10  Comment 
Amgen agreed to acquire Iceland-based deCODE genetics, which identifies genetic risk factors for dozens of diseases, for about $415 million.
Benzinga  Oct 9  Comment 
Scientists at deCODE Genetics and academic collaborators from Iceland, Norway, Denmark, the Netherlands and the USA today report the discovery of low frequency variants in the human genome that associate with risk of gout, a common inflammatory...
BusinessWeek  Mar 17  Comment 
Gene tests made by DeCode Genetics Inc., 23andMe Inc. and Navigenics Inc. add little that’s useful to what women learn about their risk for breast cancer from a family-history evaluation used for 20 years, a study found.
Globe Newswire  Mar 8  Comment 
NEW YORK, March 8, 2010 (GLOBE NEWSWIRE) -- The NASDAQ Stock Market announced today that it will delist the common stock of deCODE genetics, Inc. deCODE genetics, Inc.'s stock was suspended on January 6, 2010 and has not traded on NASDAQ since that


Formed in 1996, biotechnology company deCODE genetics, Inc. (DCGN) focuses on identifying the genetic causes of common diseases such as asthma, hypertension, and stroke, and accordingly engages in developing drugs for the treatment of these diseases. The company is using population genetics (genetic changes that happen to a population over time) to create a new paradigm for healthcare. With its uniquely comprehensive population data, deCODE is turning research on the genetic causes of common diseases into a growing range of products and services in pharmaceuticals, gene and drug discovery, DNA-based diagnostics, pharmacogenomics, bioinformatics, and clinical trials. The company has both Drug Discovery and Contract Research operations. Encode, the company's contract research organization (CRO) incorporates pharmacogenomic data to design "information rich" clinical trials. The company uses biomarkers to identify patients for optimal efficacy and drug response. Encode also develops potential pharmacogenomic (DNA) tests to be used in tandem with the drug. Encode customers include Merck, Wyeth, Pfizer, and Vertex Pharmaceuticals. The drug discovery division has both clinical and preclinical stage candidates, as well as an alliance with Roche Diagnostics. The company is based in Reykjavik, Iceland, and employs more than 400 people.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki